The Structural Heart Acceleration
Across 1 sector, 2 filers are signaling rising demand. Visible since 2024Q1, recently quiet. Primarily a demand story (80%), with a strategic overlay (20%). One disclosure notes "13.0 percent increase in sales, excluding the effect of foreign exchange, primarily reflects continued growth of the MitraClip."
Abbott is driving double-digit sales growth in its Structural Heart and Vascular segments through both organic demand (MitraClip, Navitor, endovascular products) and strategic acquisitions (CSI), with growth rates ranging from 7.6% to 14.3% excluding FX headwinds.
DISTINCT NEW FILERS PER QUARTER
✦ WHAT THE DIFF CAUGHT
Language moves from acquisition-driven growth in early filings to emphasizing underlying organic product momentum (MitraClip, Navitor) as the primary growth engine, signaling that acquired products are integrating and contributing independently to revenue expansion.
REPRESENTATIVE SIGNAL FROM FILINGS
“13.0 percent increase in sales, excluding the effect of foreign exchange, primarily reflects continued growth of the MitraClip”
Structural Heart sales increased 13.0% excluding foreign exchange effects, driven primarily by continued MitraClip growth.
“Pulmonary Hypertension products achieved operational sales growth of 6.2%”
Pulmonary Hypertension product sales grew 6.2% year-over-year.
DRIVERS